Current and emerging pharmacotherapy for pediatric allergic rhinitis

Area of Science:

• Pediatric Allergy and Immunology
• Pharmacotherapy
• Immunotherapy

Background:

• Allergic rhinitis (AR) is a growing global health issue affecting both adults and children.
• Pediatric AR presents unique challenges in prevention, compliance, and adherence compared to adults.

Purpose of the Study:

• To review pharmacotherapeutic options for allergic rhinitis, with a specific emphasis on the pediatric population.
• To discuss prevention strategies and future treatment developments for AR.

Main Methods:

• This study is a narrative review of existing literature on AR pharmacotherapy.
• Focus is placed on symptomatic treatments (steroids, antihistamines) and disease-modifying treatments (allergen immunotherapy).
• Emerging therapies, including monoclonal antibodies, are also examined.

Main Results:

• Current symptomatic treatments for AR include topical and systemic steroids and antihistamines, requiring cautious, short-term steroid use.
• Allergen immunotherapy (AIT), administered sublingually or subcutaneously, is the only causal and disease-modifying treatment available.
• Human monoclonal antibodies represent a novel therapeutic avenue for AR management.

Conclusions:

• Allergen immunotherapy holds significant future potential, with research focusing on administration routes, allergen modification, adjuvants, and nanoparticles.
• Monoclonal antibodies show promise by targeting immune mechanisms in AR.
• Preventing allergic sensitization and disease progression through AIT and biologics is crucial, particularly in the pediatric population.